Related Experiment Videos
Clinical toxicity associated with tiazofurin
J L Grem1, L Rubinstein, S A King
1Investigational Drug Branch, National Cancer Institute, Bethesda, MD 20892.
Investigational New Drugs
|May 1, 1990
Summary
Tiazofurin, an antimetabolite, shows manageable toxicity in leukemia trials. While severe myelosuppression is rare, specific schedules impact neutropenia and non-hematologic toxicities like nausea and rash.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Tiazofurin is an investigational antimetabolite used in leukemia treatment.
- Understanding its toxicity profile is crucial for optimizing clinical application.
Purpose of the Study:
- To characterize the incidence and severity of tiazofurin toxicities in leukemia patients.
- To evaluate the relationship between dose, schedule, and toxicity.
Main Methods:
- Analysis of Phase I clinical trial data from 198 leukemia patients.
- Assessment of hematologic and non-hematologic toxicities based on dose and administration schedule.
Main Results:
- Severe myelosuppression was infrequent and not dose-dependent.
- A five-day bolus schedule increased severe neutropenia risk.
- Non-hematologic toxicities included nausea, vomiting, rash, and elevated transaminases.
- Continuous infusion showed higher non-hematologic toxicity with prolonged exposure.
Conclusions:
- Tiazofurin toxicity is schedule-dependent, with continuous infusion potentially increasing non-hematologic adverse events.
- Optimizing tiazofurin dosing and scheduling is key to managing toxicity in leukemia patients.